Skip to main content
. 2020 Mar;8(5):187. doi: 10.21037/atm.2020.01.81

Table 3. Meta-analysis of recurrence.

Recurrence type No. of studies Total (n) Trastuzumab, recur/total Control, recur/total Trastuzumab vs. control, odds ratio (95% CI) P heterogeneity, I2 P value
Overall recurrence 7 1,181 10/552 (1.8%) 55/629 (8.7%) 0.201 (0.100–0.404) 0.479, 0.0% <0.001
Distant recurrence 5 673 0/237 16/436 (3.7%) 0.328 (0.082–1.311) 0.589, 0.0% 0.115

CI, confidence interval.